Advertisement
Canada markets closed
  • S&P/TSX

    22,259.47
    +312.06 (+1.42%)
     
  • S&P 500

    5,180.74
    +52.95 (+1.03%)
     
  • DOW

    38,852.27
    +176.59 (+0.46%)
     
  • CAD/USD

    0.7320
    +0.0011 (+0.15%)
     
  • CRUDE OIL

    78.82
    +0.34 (+0.43%)
     
  • Bitcoin CAD

    86,783.80
    -371.60 (-0.43%)
     
  • CMC Crypto 200

    1,368.18
    +55.55 (+4.23%)
     
  • GOLD FUTURES

    2,334.60
    +3.40 (+0.15%)
     
  • RUSSELL 2000

    2,060.67
    +24.95 (+1.23%)
     
  • 10-Yr Bond

    4.4890
    -0.0110 (-0.24%)
     
  • NASDAQ futures

    18,181.00
    -14.50 (-0.08%)
     
  • VOLATILITY

    13.49
    0.00 (0.00%)
     
  • FTSE

    8,213.49
    +41.34 (+0.51%)
     
  • NIKKEI 225

    38,236.07
    -38.03 (-0.10%)
     
  • CAD/EUR

    0.6791
    +0.0004 (+0.06%)
     

Sanofi poaches former PSA finance boss Chasseloup de Chatillon

FILE PHOTO: French multinational pharmaceutical company SANOFI logo is seen at the headquarters in Paris, France, March 8, 2016. REUTERS/Philippe Wojazer/File Photo (Reuters)

PARIS (Reuters) - French drugmaker Sanofi announced it had hired Jean-Baptiste Chasseloup de Chatillon, the former chief financial officer at carmaker and Peugeot-manufacturer PSA who had helped oversee a revival in PSA's fortunes. Sanofi said Chasseloup de Chatillon would become its executive vice-president and chief financial officer, with his position taking effect on October 1, replacing Jerome Contamine who will be retiring. "Jean-Baptiste is an experienced CFO who has been part of the impressive turnaround of PSA Group," said Sanofi chief executive Olivier Brandicourt in a statement. PSA had posted a series of record earnings results over the last two years, having rebounded from a 2012 brush with bankruptcy, and Chasseloup de Chatillon had been a member of Peugeot's managing board since 2012. Chasseloup de Chatillon will arrive at Sanofi at a time of blockbuster deals within the global healthcare industry. Sanofi has already struck two major takeover deals this year, buying haemophilia specialist Bioverativ for $11.6 billion and acquiring Ablynx, which is developing a prized experimental drug for a rare blood disorder, for 3.9 billion euros ($4.5 billion). The transactions marked a return to successful deal-making for Sanofi after failures to land major takeovers since 2011, when it bought U.S biotech company Genzyme for around $20 billion, although some investors have questioned the costs. (Reporting by Sudip Kar-Gupta and Gilles Guillaume; Editing by Bate Felix)